Granulocyte-colony stimulating growth factor

DRUG3 trials

Sponsors

Hellenic Oncology Research Group

Conditions

Breast Cancer

Phase 3

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

CompletedNCT00431080

Hellenic Oncology Research GroupBreast Cancer

Start: 2004-08-31End: 2007-10-31Updated: 2008-01-21

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

CompletedNCT00615602

Hellenic Oncology Research GroupBreast Cancer

Start: 2004-10-31End: 2012-05-31Updated: 2015-03-04

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

CompletedNCT01985724

Hellenic Oncology Research GroupBreast Cancer

Start: 2007-10-31End: 2013-12-31Updated: 2014-05-14

Related Papers

Effects of varied magnesium supply on wheat grown under ambient and elevated carbon dioxide conditions

2014-11-04

A multicenter randomized study comparing 6 versus 12 months of trastuzumab in combination with dose-dense docetaxel following FEC as adjuvant treatment of women with axillary node–positive or high-risk, node-negative breast cancer overexpressing HER2.

Journal of Clinical Oncology2014-05-201 citations